Gates Medical Research Institute news release
The Gates Medical Research Institute (Gates MRI) has reached a milestone agreement with the Serum Institute of India Private Limited (SII) to manufacture M72/AS01E, a novel TB vaccine candidate. Currently in a Phase 3 clinical trial, M72/AS01E has the potential to be the first new TB vaccine to be introduced in more than a century – a potential breakthrough against a disease that remains the world’s leading infectious cause of death and disproportionately impacts low- and middle-income countries.
This partnership marks a critical step toward ensuring that, if approved, the vaccine can be produced at scale and made available to adults and adolescents in countries with a high TB burden as soon as possible.
Read the full news release here.
For more TB updates, check out the TB CAB Weekly Newsletter (Issue #20, 17 July 2026).
The newsletter is brought to you by the Global TB Community Advisory Board (TB CAB) with the support of Treatment Action Group (TAG) and the European AIDS Treatment Group (EATG). Subscribe to the newsletter here.
Source : Gates Medical Research Institute
Related HIV and Co-Infections News
-
WHO releases implementation FAQs to accelerate uptake of new TB diagnostic recommendations
-
[Advocacy brief] TAG: Overcoming barriers to adopting the four-month regimen: A pathfinding mission to improve access to newer TB treatments
-
[Advocacy report] Results UK: Fuelling the fight against the spread of TB: Nutrition is the missing ingredient
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.